“…Regulation of ER-Ca 2+ release channels KD: decreased axonal length (Tsai et al, 2015) LOF: impaired anterograde transport (Tsai et al, 2015) AD (Mishina et al, 2008;Hedskog et al, 2013) ALS (Al-Saif et al, 2011;Prause et al, 2013) Chemotherapy-induced peripheral neuropathy (Bruna and Velasco, 2018) HD (Hyrskyluoto et al, 2013;Miki et al, 2015;Ryskamp et al, 2017) PD (Mishina et al, 2005;Mori et al, 2012) Spinal CMT (Li et al, 2015) spastin ER-Endosomes tethering MT severing LDs growth regulation KD: impaired axon outgrowth (Wood et al, 2006); reduced presynaptic area, increased excitatory junction potential amplitude, and accumulation of stabilized MTs (Trotta et al, 2004); loss of LDs (Papadopoulos et al, 2015); enhanced endosomal tubulation (Allison et al, 2013) LOF: reduced axonal length (Solowska et al, 2008); impaired regeneration (Stone et al, 2012); decreased presynaptic terminals size, decreased quantal content, and presynaptic loss of stabile MTs (Sherwood et al, 2004); large lysosomes (Allison et al, 2017) OE: reduced excitatory junction potential amplitude and presynaptic loss of stabile MTs (Trotta et al, 2004); increased LDs size and number (Papadopoulos et al, 2015) HSP (Hazan et al, 1999) STIM1 ER-PM tethering Regulation of ER-Ca 2+ uptake ER-MTs interaction KD: impaired presynaptic Ca 2+ influx and exocytosis (de Juan-Sanz et al, 2017) LOF/OE: impaired axon guidance (Shim et al, 2013) LOF: reduced ER translocation into growth cone filopodia (Pavez et al, 2019) AD (Gutierrez-Merino et al, 2018)…”